Teleflex TFX recently announced the upcoming full market release of the Advanced Tissue Control (“ATC”) feature on its unified UroLift 2 System — a platformdesigned for the treatment of benign ...

WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature journal ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Sponsored content: Enlarged prostate affects ...

WAYNE, Pa.--(BUSINESS WIRE)--NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new ...

Teleflex Incorporated TFX recently unveiled the UroLift Advanced Tissue Control (ATC) System and the UroLift 2 System together with real-world data presentations at the American Urological Association ...

WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 American ...

The committee concluded that UroLift is clinically effective, with sustained relief of lower urinary tract symptoms up to 5 years after treatment. It is implanted using a minimally invasive procedure.

Two Head-to-Head Randomized Trials Highlight Superior Early Patient Experience with the UroLift™ System for BPH 1-2 First-Ever Analysis Utilizing the American Urological Association Quality Registry ...

WAYNE, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that new data published in the peer-reviewed journal, European Urology Focus, found that men treated ...

UroLift is a minimally invasive treatment for Benign Prostatic Hyperplasia, a condition that causes an enlarged prostate in men. The procedure uses tiny implants to lift and hold the enlarged prostate ...